Medtronic (MDT) Expected to Announce Earnings on Tuesday

Key Points

• Medtronic is expected to report its Q1 2026 earnings on August 19th, with estimates of $1.23 per share and $8.37 billion in revenue.
• The company recently increased its quarterly dividend to $0.71 per share, offering a 3.1% yield to investors.
• Analysts generally have a Moderate Buy consensus rating for Medtronic, with an average target price of $98.19.

Medtronic (NYSE:MDT - Get Free Report) is expected to post its Q1 2026 quarterly earnings results before the market opens on Tuesday, August 19th. Analysts expect Medtronic to post earnings of $1.23 per share and revenue of $8.37 billion for the quarter. Medtronic has set its FY 2026 guidance at 5.500-5.600 EPS.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 21st. The medical technology company reported $1.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.04. Medtronic had a net margin of 13.90% and a return on equity of 14.54%. The business had revenue of $8.93 billion for the quarter, compared to analyst estimates of $8.81 billion. During the same period in the previous year, the business posted $1.46 earnings per share. The business's revenue was up 3.9% compared to the same quarter last year. On average, analysts expect Medtronic to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Medtronic Stock Down 0.1%

Shares of NYSE MDT opened at $92.80 on Tuesday. The firm has a 50-day moving average price of $88.83 and a 200 day moving average price of $87.94. The stock has a market capitalization of $118.95 billion, a price-to-earnings ratio of 25.63, a price-to-earnings-growth ratio of 2.41 and a beta of 0.80. Medtronic has a 52 week low of $79.29 and a 52 week high of $96.25. The company has a quick ratio of 1.42, a current ratio of 1.85 and a debt-to-equity ratio of 0.53.

Medtronic Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, July 11th. Investors of record on Friday, June 27th were given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 3.1%. This is an increase from Medtronic's previous quarterly dividend of $0.70. The ex-dividend date was Friday, June 27th. Medtronic's dividend payout ratio (DPR) is 78.45%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on MDT shares. Leerink Partners started coverage on shares of Medtronic in a research note on Monday, June 16th. They set an "outperform" rating and a $110.00 price objective for the company. Needham & Company LLC restated a "hold" rating on shares of Medtronic in a research report on Friday, June 6th. Wall Street Zen lowered Medtronic from a "buy" rating to a "hold" rating in a research report on Saturday. Leerink Partnrs upgraded Medtronic to a "strong-buy" rating in a research report on Monday, June 16th. Finally, Robert W. Baird lowered their price objective on shares of Medtronic from $94.00 to $92.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Twelve analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $98.19.

Hedge Funds Weigh In On Medtronic

An institutional investor recently raised its position in Medtronic stock. Brighton Jones LLC boosted its stake in shares of Medtronic PLC (NYSE:MDT - Free Report) by 1,368.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 39,989 shares of the medical technology company's stock after purchasing an additional 37,265 shares during the period. Brighton Jones LLC's holdings in Medtronic were worth $3,194,000 at the end of the most recent reporting period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.